Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEOGENOMICS INC Director's Dealing 2017

May 2, 2017

32227_dirs_2017-05-02_91cc8063-69e3-4689-b659-728a428e8cca.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2017-04-28

Reporting Person: BRODIE STEVEN G. (Vice President of Operations)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-04-28 Stock Option (Right to Buy) $7.52 A 50000 Acquired 2022-04-28 Common Stock (50000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 25953 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $3.45 2019-03-05 Common Stock (20000) 20000 Direct
Stock Option (Right to Buy) $4.78 2020-05-04 Common Stock (120000) 120000 Direct
Stock Option (Right to Buy) $7.15 2021-04-20 Common Stock (100000) 100000 Direct

Footnotes

F1: On March 5, 2014, Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date.

F2: On May 4, 2015, Dr. Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.

F3: On April 20, 2016, Dr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On April 28, 2017, Dr. Brodie was granted 50,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.